rs193922103

Variant summary

Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong

The NM_000053.4(ATP7B):ā€‹c.2305A>Gā€‹(p.Met769Val) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000252 in 1,614,022 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā˜…ā˜…). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M769I) has been classified as Likely pathogenic.

Frequency

Genomes: š‘“ 0.00014 ( 0 hom., cov: 32)
Exomes š‘“: 0.00026 ( 0 hom. )

Consequence

ATP7B
NM_000053.4 missense

Scores

9
8
2

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:18

Conservation

PhyloP100: 7.96
Variant links:
Genes affected
ATP7B (HGNC:870): (ATPase copper transporting beta) This gene is a member of the P-type cation transport ATPase family and encodes a protein with several membrane-spanning domains, an ATPase consensus sequence, a hinge domain, a phosphorylation site, and at least 2 putative copper-binding sites. This protein is a monomer, and functions as a copper-transporting ATPase which exports copper out of the cells, such as the efflux of hepatic copper into the bile. Alternate transcriptional splice variants, encoding different isoforms with distinct cellular localizations, have been characterized. Mutations in this gene have been associated with Wilson disease which is characterized by copper accumulation. [provided by RefSeq, Dec 2019]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 16 ACMG points.

PM1
In a transmembrane_region Helical (size 20) in uniprot entity ATP7B_HUMAN there are 12 pathogenic changes around while only 0 benign (100%) in NM_000053.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chrnull-null-null-null is described in UniProt as null.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.862
PP5
Variant 13-51958361-T-C is Pathogenic according to our data. Variant chr13-51958361-T-C is described in ClinVar as [Pathogenic]. Clinvar id is 35706.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr13-51958361-T-C is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
ATP7BNM_000053.4 linkuse as main transcriptc.2305A>G p.Met769Val missense_variant 8/21 ENST00000242839.10 NP_000044.2

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
ATP7BENST00000242839.10 linkuse as main transcriptc.2305A>G p.Met769Val missense_variant 8/211 NM_000053.4 ENSP00000242839 P1P35670-1

Frequencies

GnomAD3 genomes
AF:
0.000138
AC:
21
AN:
152130
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000241
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000294
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000681
AC:
17
AN:
249552
Hom.:
0
AF XY:
0.0000517
AC XY:
7
AN XY:
135390
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000150
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000264
AC:
386
AN:
1461892
Hom.:
0
Cov.:
31
AF XY:
0.000264
AC XY:
192
AN XY:
727248
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.0000504
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.000335
Gnomad4 OTH exome
AF:
0.000149
GnomAD4 genome
AF:
0.000138
AC:
21
AN:
152130
Hom.:
0
Cov.:
32
AF XY:
0.000121
AC XY:
9
AN XY:
74318
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000294
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.000152
Hom.:
0
Bravo
AF:
0.000110
TwinsUK
AF:
0.000270
AC:
1
ALSPAC
AF:
0.000778
AC:
3
ESP6500AA
AF:
0.000248
AC:
1
ESP6500EA
AF:
0.000120
AC:
1
ExAC
AF:
0.0000661
AC:
8
EpiCase
AF:
0.000218
EpiControl
AF:
0.000178

ClinVar

Significance: Pathogenic
Submissions summary: Pathogenic:18
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Wilson disease Pathogenic:12
Pathogenic, criteria provided, single submitterclinical testingLaboratory for Molecular Medicine, Mass General Brigham Personalized MedicineJun 11, 2020The p.Met769Val variant in ATP7B has been identified in the homozygous or compound heterozygous state in at least 6 individuals with Wilson disease (Curtis 1999, Caca 2001, Lepori 2007, Nicastro 2009, Weiss 2010, Moller 2011). It has also been identified in 0.016% (20/128686) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org) and reported in ClinVar (Variation ID 35706). In vitro functional studies support an impact on protein function (Forbes 2000, Huster 2012, ). In addition, computational prediction tools and conservation analyses are consistent with pathogenicity. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive Wilson disease. ACMG/AMP criteria applied: PM3_VeryStrong, PM2_Supporting, PP3, PP4, PS3_Supporting. -
Pathogenic, criteria provided, single submitterclinical testingAll of Us Research Program, National Institutes of HealthFeb 05, 2024This missense variant replaces methionine with valine at codon 769 of the ATP7B protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown conflicting results on this variant's impact on copper transport activity (PMID: 9837819, 10942420, 12557139, 18203200, 17717039, 22240481, 22806248). This variant has been reported in individuals affected with Wilson disease (PMID: 10502777, 11405812, 11690702, 15202786, 17449133, 17949296, 19118915, 20082719, 20517649, 21610751, 23518715, 23982005, 27022412, 27706781, 29321352, 29431110, 31980526, 33159804, 33640437, 34400371). In a number of these individuals, this variant was confirmed to be in the compound heterozygous state (PMID: 29321352, 33159804, 33640437) or the homozygous state (PMID: 19118915, 22806248, 32028086). This variant has been identified in 20/280946 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpJan 03, 2024This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 769 of the ATP7B protein (p.Met769Val). This variant is present in population databases (rs193922103, gnomAD 0.01%). This missense change has been observed in individual(s) with Wilson disease (PMID: 7626145, 11690702, 19118915, 20517649, 21610751). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 35706). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATP7B protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects ATP7B function (PMID: 9837819, 22240481). For these reasons, this variant has been classified as Pathogenic. -
Pathogenic, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoAug 14, 2017- -
Pathogenic, criteria provided, single submitterclinical testingGenome-Nilou LabAug 10, 2021- -
Pathogenic, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesJan 11, 2019The ATP7B c.2305A>G; p.Met769Val variant (rs193922103) is reported in the literature in the compound heterozygous or homozygous state in multiple individuals affected with Wilson disease (Caca 2001, Curtis 1999, Garcia-Villarreal 2000, Moller 2011, Nicastro 2009, Weiss 2010, Wu 2001). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 35706), and is found in the non-Finnish European population with an allele frequency of 0.016% (20/128,686 alleles) in the Genome Aggregation Database. The methionine at codon 769 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Functional analyses of the variant protein show reduced copper transport activity (Forbes and Cox 1998, Huster 2012). Based on available information, this variant is considered to be pathogenic. References: Caca K et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol. 2001 Nov;35(5):575-81. Curtis D et al. A study of Wilson disease mutations in Britain. Hum Mutat. 1999;14(4):304-11. Forbes JR and Cox DW et al. Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet. 1998 Dec;63(6):1663-74. Garcia-Villarreal L et al. High prevalence of the very rare Wilson disease gene mutation Leu708Pro in the Island of Gran Canaria (Canary Islands, Spain): a genetic and clinical study. Hepatology. 2000 Dec;32(6):1329-36. Huster D et al. Diverse functional properties of Wilson disease ATP7B variants. Gastroenterology. 2012 Apr;142(4):947-956.e5. Moller LB et al. Clinical presentation and mutations in Danish patients with Wilson disease. Eur J Hum Genet. 2011 Sep;19(9):935-41. Nicastro E et al. Genotype-phenotype correlation in Italian children with Wilson's disease. J Hepatol. 2009 Mar;50(3):555-61. Weiss KH et al. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S233-40. Wu ZY et al. Mutation analysis and the correlation between genotype and phenotype of Arg778Leu mutation in chinese patients with Wilson disease. Arch Neurol. 2001 Jun;58(6):971-6. -
Pathogenic, criteria provided, single submitterclinical testingRevvity Omics, RevvityDec 20, 2022- -
Pathogenic, criteria provided, single submitterclinical testingMyriad Genetics, Inc.Dec 24, 2019NM_000053.3(ATP7B):c.2305A>G(M769V) is classified as pathogenic in the context of Wilson disease. Sources cited for classification include the following: PMID 9837819, 19118915, 23518715, 22692182, 24253677, 22240481 and 10942420. Classification of NM_000053.3(ATP7B):c.2305A>G(M769V) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. -
Pathogenic, criteria provided, single submitterclinical testing;curationWomen's Health and Genetics/Laboratory Corporation of America, LabCorpAug 18, 2011- -
Pathogenic, criteria provided, single submitterclinical testingBaylor GeneticsMar 27, 2024- -
Pathogenic, no assertion criteria providedclinical testingNatera, Inc.Sep 16, 2020- -
Pathogenic, criteria provided, single submitterclinical testingFulgent Genetics, Fulgent GeneticsApr 25, 2022- -
not provided Pathogenic:5
Pathogenic, criteria provided, single submitterclinical testingAiLife Diagnostics, AiLife DiagnosticsNov 17, 2021- -
Pathogenic, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenSep 01, 2023ATP7B: PM1, PM2, PM3, PM5, PP3, PS3:Supporting -
Pathogenic, criteria provided, single submitterclinical testingGeneDxFeb 23, 2024Observed multiple times with a second ATP7B pathogenic variant in unrelated patients with Wilson disease referred for genetic testing at GeneDx and in published literature; however, it is not known whether the variants occurred on the same allele (in cis) or on different alleles (in trans) in all cases (PMID: 33159804, 20517649, 21610751); Published functional studies found M769V is associated with significantly reduced copper uptake and decreased thermal stability compared to wildtype (PMID: 22240481, 9837819); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 9311736, 11405812, 19118915, 24253677, 18371106, 21610751, 34400371, 35271763, 9837819, 20517649, 7626145, 11093740, 22692182, 23518715, 10502777, 27022412, 29431110, 17717039, 16939419, 14986826, 11690702, 12557139, 10942420, 29321352, 31980526, 33159804, 27535533, 22240481) -
Pathogenic, criteria provided, single submitterclinical testingMayo Clinic Laboratories, Mayo ClinicDec 15, 2021PP3, PM1, PM2, PM5 -
Pathogenic, criteria provided, single submitterclinical testingEurofins Ntd Llc (ga)Jun 28, 2016- -
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJun 22, 2017The p.M769V pathogenic mutation (also known as c.2305A>G), located in coding exon 8 of the ATP7B gene, results from an A to G substitution at nucleotide position 2305. The methionine at codon 769 is replaced by valine, an amino acid with highly similar properties. This mutation was reported in multiple unrelated individuals (Curtis D et al. Hum. Mutat., 1999;14:304-11; García-Villarreal L et al. Hepatology, 2000 Dec;32:1329-36; Caca K et al. J. Hepatol., 2001 Nov;35:575-81; Weiss KH et al. J. Inherit. Metab. Dis., 2010 Dec;33 Suppl 3:S233-40), including two homozygous individuals with hepatic Wilson disease (Nicastro E et al. J. Hepatol., 2009 Mar;50:555-61). Functional studies demonstrated that this mutation impairs the protein function (Forbes JR et al. Am. J. Hum. Genet., 1998 Dec;63:1663-74; Huster D et al. Gastroenterology, 2012 Apr;142:947-956.e5). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.50
BayesDel_addAF
Pathogenic
0.27
D
BayesDel_noAF
Pathogenic
0.38
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.80
D;.;.;.
Eigen
Uncertain
0.52
Eigen_PC
Uncertain
0.57
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Pathogenic
0.99
D;D;D;D
M_CAP
Pathogenic
0.39
D
MetaRNN
Pathogenic
0.86
D;D;D;D
MetaSVM
Pathogenic
0.90
D
MutationAssessor
Benign
1.3
L;.;.;.
MutationTaster
Benign
1.0
A;A;A;A;A;A;A
PrimateAI
Uncertain
0.75
T
PROVEAN
Uncertain
-3.2
D;D;.;D
REVEL
Pathogenic
0.91
Sift
Pathogenic
0.0
D;D;.;D
Sift4G
Uncertain
0.0020
D;D;D;D
Polyphen
1.0
D;B;D;D
Vest4
0.85
MVP
0.88
MPC
0.38
ClinPred
0.40
T
GERP RS
5.4
Varity_R
0.84
gMVP
0.80

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs193922103; hg19: chr13-52532497; API